|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We utilized 18-month-old endothelial nitric oxide synthase (eNOS) heterozygous knockout (<sup>+/-</sup>) mice, a clinically relevant model of endothelial dysfunction, to examine the role of endothelial nitric oxide (NO) in vascular Aβ accumulation. eNOS<sup>+/-</sup> mice had significantly higher vascular levels of Aβ40 ( P < 0.05).Aβ42 was not detected.
|
30614363 |
2020 |
|
Endothelial dysfunction
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
These findings indicated that down-expression of -786T>C located on the promoter of eNOS is associated with an increased risk of endothelial dysfunction.
|
31209933 |
2020 |
|
Endothelial dysfunction
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The underlying causes of endothelial dysfunction with sex hormone deficiency are unknown but may be related to endothelial nitric oxide synthase dysfunction and oxidative stress.
|
30632767 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this study, we reveal differential expression of several genes related to lipid retention and apoptosis, in conjunction with atherosclerosis, by utilizing a genetic mouse model of endothelial nitric oxide synthase (eNOS) deficiency manifesting endothelial dysfunction.
|
30638179 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mulberry Extract Attenuates Endothelial Dysfunction through the Regulation of Uncoupling Endothelial Nitric Oxide Synthase in High Fat Diet Rats.
|
31035424 |
2019 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The combination of RE and MP could be used for the treatment of hypertension and could improve microcirculation, upregulate eNOS expression, and mitigate endothelial dysfunction in SHR.
|
29576700 |
2019 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The protective effect of RSV against MGO-induced endothelial dysfunction seems to be via increased eNOS expression and activity.
|
29951747 |
2019 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The histone deacetylase inhibitor tubacin mitigates endothelial dysfunction by up-regulating the expression of endothelial nitric oxide synthase.
|
31719145 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The Ang II/type 1 receptor (AT<sub>1</sub>R) signaling pathway can cause endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) dysfunction through various mechanisms leading to ED.
|
31239152 |
2019 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Polymorphisms and epigenetic-sensitive mechanisms can modulate the expression of eNOS gene, leading to the endothelial dysfunction.
|
30741027 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Structural uncoupling of eNOS, with generation of enzyme monomers, is thought to contribute to endothelial dysfunction in several vascular disorders, including aging.
|
30289292 |
2019 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
XJEK improved the heart systolic and diastolic function, ameliorated hemodynamic parameters and cardiovascular remodeling indices, blunted the cardiac pathological changes and improved endothelial dysfunction (ED) via boosting eNOS activity, promoting NO bioavailability and decreasing serum Ang II content.
|
30783421 |
2019 |
|
Endothelial dysfunction
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We investigated whether an administration of exogenous of GSNO or enhancing the level of endogenous GSNO protects against neurovascular injury in wild-type (WT) and eNOS-null (endothelial dysfunction) mouse models of cerebral ischemia-reperfusion (IR).
|
31680031 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We sought to define the factors inducing inflammation and smooth muscle foam cell formation under endothelial dysfunction using endothelial nitric oxide synthase (eNOS)-deficient mice.
|
31379881 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Asymmetric dimethylarginine (ADMA), an endothelial nitric oxide synthase inhibitor, plays a crucial role in the pathogenesis of various cardiovascular diseases associated with endothelial dysfunction.
|
30951718 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study tested the hypothesis that fenofibrate could ameliorate endothelium-dependent vasodilation in diabetic mice and relieve high glucose-induced endothelial dysfunction via activating endothelial nitric oxide synthase (eNOS) and adenosine monophosphate-activated protein kinase (AMPK) phosphorylation.
|
30970521 |
2019 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Collectively, the available data suggest that the augmentation of endothelial KLF5 expression by hyperinsulinemia may represent a novel mechanism for negatively regulating eNOS expression, and may thus help to explain for the T2DM-related endothelial dysfunction at the transcriptional level.
|
31049798 |
2019 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Intracellular signaling pathways, which interplay between arginase and eNOS enzyme activity leading to the development of endothelial dysfunction in hyperglycemia are not fully understood.
|
31150695 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Endothelial nitric oxide synthase enhancer AVE3085 reverses endothelial dysfunction induced by homocysteine in human internal mammary arteries.
|
30300735 |
2018 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
EUL extract and aucubin also led to recovery of phospho-eNOS Thr495 expression, a critical signaling component in eNOS uncoupling, suggesting that EUL has regulatory effects against eNOS uncoupling and might play preventive/regulatory roles against vascular endothelial dysfunction.
|
29136955 |
2018 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Decreased eNOS activity and phosphorylation resulting in a low NO production state featuring pulmonary endothelial dysfunction was an early event in breast cancer pulmonary metastasis, preceding the onset of its phenotypic switch toward a mesenchymal phenotype (EndMT) evidenced by a decrease in VE-CAD and CD31 expression.
|
30075800 |
2018 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Yet, this is paradox: (1) free ADMA and SDMA are weak inhibitors of endothelial NOS (eNOS) which is primarily responsible for NO-related effects in the cardiovascular system, with free hArg being a poor substrate for eNOS; (2) free ADMA, SDMA and hArg are not associated with oxidative stress which is considered to induce NO-related endothelial dysfunction.
|
29301528 |
2018 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, animal models of endothelial dysfunction and endothelial nitric oxide synthase (eNOS) uncoupling had a very high rate of AAA formation, indicating there is crucial involvement of the endothelium and a possible pharmacological solution targeting the endothelium in AAA treatment.
|
29849906 |
2018 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We found that circulating exosomes contributed to the induction and propagation of OSA/OHS-related endothelial dysfunction (ie, increased permeability and disruption of tight junctions along with increased adhesion molecule expression, and reduced endothelial nitric oxide synthase expression), and promoted increased monocyte adherence.
|
29734990 |
2018 |
|
Endothelial dysfunction
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Simvastatin and atorvastatin improve endothelial dysfunction mainly by enhancing endothelial nitric oxide synthase (eNOS) expression and phosphorylation and NO production.
|
29210030 |
2018 |